|
Thursday 25th February 2021 |
Text too small? |
In November 2020 Gentrack Group Limited (NZX/ASX: GTK) (“Gentrack”) advised that it expected that the full year EBITDA run rate for FY21 would be well below that of the H2 FY20 run rate and that FY21 profitability may be reduced closer to break-even depending on the levels of future product investment and other factors.
Gentrack now provides the following outlook update:
•FY21 revenues are expected to be close to or slightly ahead of FY20 revenues of $100.5m
•FY21 EBITDA is expected to be around $5m on the basis that research and development (R&D) costs are expensed
•Incremental R&D costs are expected to be ~$3m/quarter from Q3 FY21
•The company expects to be net cashflow positive in FY21, building on the $16.8m of net cash reported at 30th September 2020.
Profit and cashflow are expected to be weighted to H1 FY21 given the incremental R&D spend forecast for H2.
Please see the link below for details:
Source: Gentrack Group Limited
No comments yet
RYM - Ryman Healthcare appoints new independent director
ikeGPS 4Q FY26 and Full Year FY26 Performance Update
HGH - Heartland trading update
CVT - Comvita Rights Offer Opens
GNE - FY26 Q3 Performance Report and Updated Guidance
April 23rd Morning Report
Devon Funds Morning Note - 22 April 2026
AGL - Accordant Group Limited announces opening of Rights Offer
April 22nd Morning Report
BPG - Q4 FY26 Update: ARR reaches $26.8m